Cite
HARVARD Citation
Migliorini, D. et al. (n.d.). 531 MVX-ONCO-1: First in man, Phase I clinical trial combining encapsulation cell technology and irradiated autologous tumor cells for personalized cell-based immunotherapy. Safety, feasibility and clinical outcome results. European journal of cancer. pp. S114-. [Online].